Literature DB >> 808562

Induction of antibodies to nuclear antigens in rabbits by immunization with hydralazine-human serum albumin conjugates.

Y Yamauchi, A Litwin, L Adams, H Zimmer, E V Hess.   

Abstract

The antihypertensive drug hydralazine can induce in man a syndrome similar to spontaneous systemic lupus erythematosus (SLE). The pathogenesis of this drug-induced syndrome is not understood. In this investigation, five groups of rabbits were studied: group I, 10 rabbits hyperimmunized with hydralazine conjugated to human serum albumin (HSA) in complete Freund's adjuvant (CFA); group II, four rabbits with HSA in CFA; group III, four rabbits with CFA alone; group IV, five rabbits with hydralazine conjugated to rabbit serum albumin (RSA); and group V, four rabbits with a major metabolite of hydralazine conjugated to HSA. The rabbits immunized with hydralazine-HSA developed rising titers of antibodies to hydralazine and progressively increasing amounts of antibodies to both single-stranded and native DNA. The antibodies to DNA were cross-reactive with hydralazine as determined by inhibition of DNA binding and DNA hemagglutination tests. Similar results were obtained in rabbits immunized with the metabolite-HSA compound except the major hapten antibody response was to the metabolite. The DNA antibodies in this group were also capable of being absorbed by metabolite-HSA as well as hydralazine-HSA, indicative of the cross-reactivity between hydralazine and its metabolite. Immunization with hydralazine-RSA caused rabbits to produce antibodies to hydralazine but not to DNA, indicating the requirement for an immune response to the carrier protein in order for antibodies reactive with DNA to be produced. Thus, hyperimmunization of rabbits with hydralazine-protein conjugates may provide a useful animal model of SLE. The data suggests that an immune response to hydralazine may be important in human hydralazine-induced SLE.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 808562      PMCID: PMC301952          DOI: 10.1172/JCI108176

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Hydralazine disease in the guinea-pig as an experimental model for lupus erythematosus.

Authors:  I M BRAVERMAN; A B LERNER
Journal:  J Invest Dermatol       Date:  1962-10       Impact factor: 8.551

2.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

3.  Demonstration of anti-hydralazine antibody in hydralazine induced lupus erythematosus.

Authors:  H FRIEDMAN; W I HEINE
Journal:  Experientia       Date:  1963-01-15

4.  Experimental attempt to produce L-E syndrome (arthritis) in swine with hydralazine.

Authors:  F W McCOY; W J LEACH
Journal:  Proc Soc Exp Biol Med       Date:  1959-05

5.  The response of the dog to oral L-hydrazinophthalazine (hydralazine).

Authors:  D L GARDNER
Journal:  Br J Exp Pathol       Date:  1957-04

6.  [Hydralazine-induced lupus erythematosus].

Authors:  F SIGUIER; C BETOURNE; J BONNET DE LA TOUR
Journal:  Sem Hop       Date:  1958-03-18

7.  Anti-DNA antibody in procainamide-induced lupus erythematosus. Determinations using DNA fractionated by methylated albumin-Kieselguhr chromatography.

Authors:  J B Winfield; J S Davis
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

Review 8.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

9.  Induction, maintenance and termination of immunologic unresponsiveness to bovine thyroglobulin in rabbits.

Authors:  R M Nakamura; W O Weigle
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

10.  Chronic toxicity studies of hydralazine (apresoline) in dogs with particular reference to the production of the hydralazine syndrome.

Authors:  E L DUBOIS; Y J KATZ; V FREEMAN; F GARBAK
Journal:  J Lab Clin Med       Date:  1957-07
View more
  6 in total

Review 1.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

2.  Drug metabolising activity of freshly isolated human hepatocytes.

Authors:  L B Tee; T Seddon; A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

Review 3.  Drug-induced antinuclear antibodies and lupus syndromes.

Authors:  D Alarcón-Segovia
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis.

Authors:  R N Hobbs; A L Clayton; R M Bernstein
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

5.  Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.

Authors:  W A Bogers; L Meems
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Hydralazine target: from blood vessels to the epigenome.

Authors:  Claudia Arce; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Myrna Candelaria; Alfonso Dueñnas-Gonzalez
Journal:  J Transl Med       Date:  2006-02-28       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.